The current trend in cancer treatment is to enable the immune system of the patient to eradicate the tumors instead of using chemotherapy to target the cancer cells. Seattle Genetics is a leading biotechnology firm that specializes in development and commercialization of advanced antibody-based therapies for cancer treatment. Seattle Genetics is a market leader and supplier of the antibody-drug conjugate, an innovative technology developed to strengthen the targeting capability of monoclonal antibodies in delivering cell-killing agents straight to the cancer cells. ADCs are designed to avoid non-targeted cells hence minimizing harmful effects associated with traditional chemotherapy and promoting antitumor activity.
ADCETRIS is Seattle’s top program and an innovative class of ADCs. The drug has been approved in over 60 countries. The firm is currently carrying out a clinical development program to evaluate if ADCETRIS can treat CD30-expressing lymphomas such as cutaneous T-cell lymphoma, mature T-cell lymphomas, and Hodgkin lymphoma.
This ADC is being examined in pivotal phase 3 experimentation for the treatment of acute myeloid leukemia (AML). AML is a vital unmet need since patient outcomes have remained unchanged for over 30 years.
33A and ADCETRIS are part of over 20 ADCs currently in clinical development utilizing Seattle Genetics’ proprietary technology such as over 12 internal clinical as well as preclinical programs. The company is striving to come up with a lasting solution for solid tumors and hematologic malignancies.
Clay B. Siegall was one of the co-founders of Seattle Genetics in 1998, and he currently serves as the CEO, Board Chairman, and President. He is a trained scientist who has specialized in targeted cancer therapies. He created Seattle Genetics on a firm basis of scientific innovation, thorough research, drug creation practices, and commitment to helping patients. He has played an integral role in steering the company to a top position in the health care industry and in obtaining the authorization of its first innovative ADC product by the FDA. Dr. Siegall has led Seattle Genetics in entering into several tactical licenses for its groundbreaking ADC technology with AbbVie, Pfizer, Genentech, and GlaxoSmithKline, which have produced over $325 million.